Advertisement
Research Article

An Integrated Disease/Pharmacokinetic/Pharmacodynamic Model Suggests Improved Interleukin-21 Regimens Validated Prospectively for Mouse Solid Cancers

  • Moran Elishmereni,

    Affiliation: Institute for Medical Biomathematics (IMBM), Bene-Ataroth, Israel

    X
  • Yuri Kheifetz,

    Affiliation: Institute for Medical Biomathematics (IMBM), Bene-Ataroth, Israel

    X
  • Henrik S√łndergaard,

    Affiliation: Novo Nordisk A/S, Malov, Denmark

    X
  • Rune Viig Overgaard,

    Affiliation: Novo Nordisk A/S, Malov, Denmark

    X
  • Zvia Agur mail

    agur@imbm.org

    Affiliations: Institute for Medical Biomathematics (IMBM), Bene-Ataroth, Israel, Optimata Ltd., Ramat-Gan, Israel

    X
  • Published: September 29, 2011
  • DOI: 10.1371/journal.pcbi.1002206

Reader Comments (0)

Post a new comment on this article